CoreLab Partners, Inc, an independent core lab providing centralized cardiac safety services and medical imaging assessment, has launched new imaging capabilities targeted at the utilization of independent central image review in the detection of early Alzheimer’s disease.
“Recognizing the ongoing evolution of magnetic resonance imaging (MRI), positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging in dementia-related clinical trials, CoreLab Partners has put into place a team of knowledgeable experts combined with advanced technological tools to ensure current and emerging image assessment needs are met” stated Dr. Michael Woehler, President & CEO. “This exciting new capability is a natural extension of our industry-leading suite of imaging science solutions and marks a significant milestone in the utilization of scientifically validated tools designed to accurately quantify brain structure volumetric data” added Woehler.
Senior members of the CoreLab Partners’ medical affairs team will be attending CBIs upcoming 6th Annual Alzheimer’s Drug Development Summit to be held in Philadelphia, PA from December 11 – 12, 2012; please join us for this important industry event as the scientific community shares their future perspectives from the Dominantly Inherited Alzheimer Network (DIAN).
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.